House Bill Would Pay Drugmakers to Stockpile 6-Month Supply of Critical Medicines
RAPID Reserve Act
Stalled
No legislative action in over 90 days.
Legislative Progress
Key Points
Impact Analysis
Personal Impact
How this policy affects specific groups of people
Milestones
What Happens Next
Projected impacts based on AI analysis
Related News
4 articlesSenate bill aims to rebuild drug manufacturing infrastructure: 3 notes
Bipartisan senators reintroduced the RAPID Reserve Act to address generic drug shortages by expanding domestic stockpiles and manufacturing capacity. The bill requires HHS to award contracts to U.S. or allied manufacturers to maintain reserves of essential medications and ingredients.
Senators bring back bill to bolster US pharma supply chain by awarding contracts to domestic producers
The Rolling Active Pharmaceutical Ingredient and Drug (RAPID) Reserve Act would require HHS to issue contracts to U.S.-based or OECD-based drugmakers to maintain reserves of critical medications and key ingredients, aiming to reduce overreliance on China and improve preparedness.
Pharmaceutical Blackout: The Hidden Threat to U.S. Security
Authors argue that the RAPID Reserve Act is a 'legislative lifeline' designed to prevent 'pharmacological blackouts' by bringing critical medicine manufacturing back to U.S. shores and building strategic reserves of generic drugs currently dependent on Chinese and Indian supply chains.
Source Information
Analysis generated by AI. Always verify with official sources.